26 February 2021 08:31ZICCUM AB feedback to EU: “Pandemic preparation demands innovation in vaccine formulation”
As part of Ziccum’s strategy of actively reaching out to global vaccine policymakers worldwide, Ziccum CEO Göran Conradson has submitted formal feedback to the EU’s consultation for the European Health Emergency Preparedness and Response...
11 February 2021 08:00ZICCUM AB Year-end report January 1- December 31, 2020
Summary of year-end report, fourth quarter 2020 During the fourth quarter, Ziccum announced that it had carried out a pilot study on large-scale production of temperature-stable vaccines. The pilot study centred on a Fill and Finish facility (the last...
11 February 2021 08:00ZICCUM AB Bokslutskommuniké 1 januari- 31 december 2020
Sammanfattning av delårsrapporten - fjärde kvartalet 2020 Under fjärde kvartalet meddelade Ziccum att en pilotstudie på storskalig produktion av temperaturstabila vacciner har genomförts. Pilotstudien avser en Fill and finish-anläggning...
25 January 2021 18:40Ziccum extends evaluation agreement with global pharmaceutical company
Lund, January 25, 2021 -- Ziccum AB (publ) (‘Ziccum’) entered into an evaluation study agreement on 3 Oct 2019 with Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Based on positive...
25 January 2021 18:40Ziccum förlänger utvärderingsavtal med globalt läkemedelsföretag.
Lund, 25 januari 2021. Ziccum AB (publ) (‘Ziccum’) ingick ett utvärderingsavtal 3 oktober 2019 med Janssen Vaccine & Prevention B.V., en av Janssens läkemedelsbolag som tillhör Johnson & Johnson. Baserat på de...
12 January 2021 13:00Ziccum presents corporate goals for 2021
Lund, 12 January 2021. Ziccum's major goals for 2021 are to enter into its first licensing agreement for a dry-formulated vaccine, and to present a detailed plan for establishing a Fill and Finish production facility for the filling and final packaging...
12 January 2021 13:00Ziccum presenterar målsättningar för 2021
Lund, 12 januari 2021. Ziccums huvudmål för 2021 är att ingå Bolagets första licensavtal, samt att presentera en detaljerad plan för att etablera en produktionsanläggning för fyllning och slutförpackning...
1 December 2020 08:00Idag inleds handeln av Ziccums aktie på Nasdaq First North Growth Market
Ziccum AB (”Ziccum” eller ”Bolaget”) meddelar att handeln av Bolagets aktie på Nasdaq First North Growth Market inleds i dag under kortnamn ”ZICC” med ISIN SE0011415595. Göran Conradson, VD, kommenterar...
16 November 2020 12:32Market Notice 280/20 – Ziccum AB will be delisted after close of the market on November 30, 2020
Ziccum AB will be delisted from Spotlight after close of the market on November 30, 2020. For more information, see the press release from the company. Information about the share:
Shortname: ZICC
ISIN-code: SE0011415595
Orderbook-ID: 4NG9
CFI...
11 November 2020 12:52Ziccum AB carries out list change to Nasdaq First North Growth Market and releases company description
Ziccum AB ("Ziccum" or "the Company") announces today, November 11, 2020, that it has received approval for admission to trade on the Nasdaq First North Growth Market. The first day of trading on the Nasdaq First North Growth Market...
11 November 2020 12:52Ziccum AB genomför listbyte till Nasdaq First North Growth Market och offentliggör bolagsbeskrivning
Ziccum AB ("Ziccum" eller "Bolaget") har idag den 11 november 2020 erhållit godkännande för upptagande till handel på Nasdaq First North Growth Market. Första dag för handel på Nasdaq First North...
6 November 2020 08:00ZICCUM AB Delårsrapport 1 januari-30 september 2020
Sammanfattning av delårsrapporten under tredje kvartalet 2020 Ziccum har under tredje kvartalet gjort stora framsteg i arbetet med att industrialisera sin unika process för att framställa vacciner i torr pulverform. Stora ekonomiska och...
6 November 2020 08:00ZICCUM AB interim report January 1-September 30, 2020
Summary of interim report, third quarter 2020 During the third quarter Ziccum made great progress in its work of industrializing its unique process for producing vaccines in dry powder form. Major economic and production-technical advantages have been...
3 November 2020 13:00ZICCUM AB releases blueprint of world’s first industrial plant producing air-dried vaccines requiring no Cold Chain
"Vaccinating the world against COVID-19 will be one of the largest mass undertakings in human history" - as UNICEF, the WHO, analysts, NGOs and governments worldwide warn of the escalating challenge the Cold Chain represents to vaccine coverage...
26 October 2020 15:17ZICCUM AB har utsett Frida Hjelmberg till ny CFO
(Lund, Sverige, oktober 26 2020) Ziccum AB har utsett Frida Hjelmberg till ny CFO fr.o.m 1 januari 2021.Frida har senast varit CFO på Spares Nordic AB från 2018 och tidigare anställd bl.a. som Head of Accounting, Egmont samt som revisor...
19 October 2020 08:00ZICCUM publicerar White Paper som beskriver världens första anläggning för storskalig produktion av temperaturstabila vacciner
Ziccums White Paper ger en detaljerad beskrivning av hur bolagets teknik LaminarPace integreras i en s.k. Fill and Finish-anläggning som blir världens första anläggning för storskalig produktion av temperaturstabila vacciner...
19 October 2020 08:00ZICCUM to publish White Paper on world’s first industrial air-drying of vaccines using its LaminarPace technology
The White Paper will describe in detail the integration of Ziccum AB’s LaminarPace technology into a Fill and Finish (F/F) manufacturing facility of the world’s first plant for formulating and packaging thermostable air-dried vaccines at volume...
15 October 2020 08:43ZICCUM har genomfört en pilotstudie på storskalig produktion av temperaturstabila vacciner i partnerskap med KeyPlants
Ziccum har genomfört en pilotstudie av en Fill and Finish-anläggning, med syfte att utvärdera den tekniska och finansiella bärkraften av kommersiell produktion av temperaturstabila vacciner. Studien som är genomförd i samarbete...
15 October 2020 08:43ZICCUM takes lead on new pilot study of vaccine plant producing cost-effective thermostable vaccines at volume with KeyPlants as engineering partner
Ziccum has produced a pilot study, including blueprints and costings, exploring the technical and financial viability of a Fill and Finish plant producing thermostable air-dried vaccines at volume. The plan, produced in collaboration with leading modular...
15 September 2020 08:01ZICCUM AB: global vaccine cold chain moves to top of news agenda as world calls for action
The challenge facing global vaccine supply chains has moved firmly to the top of the global news and healthcare agenda over the last week. From UNICEF to the BBC to the University of Birmingham, headlines like ‘8,000 jumbo jets needed to deliver...